BioSpace News Archive

Policy

Drug-Pricing Watchdog Thinks Biogen’s Spinraza Cost Should Be Less

The current Spinraza cost is $750,000 for the first year and $375,000 for every year after for the life of the patient. It is approved for all forms of SMA.

April 4, 2019
·
4 min read
·
Mark Terry
Business

Roivant and Sinovant Launch Cytovant in $1 Billion-Plus Deal With MediGene

Partnering with Hong Kong-based Sinovant Sciences, which is one of Ramaswamy’s “vant” companies, Roivant and Sinovant are launching a company called Cytovant Sciences.

April 4, 2019
·
3 min read
·
Mark Terry
Career Advice

From Interview to Offer: 8 Best Job Search Tips

To navigate each step along the way from an interview to a final offer, you should have a clear understanding of a timeline of events. These job search tips can help you with that.

April 4, 2019
·
3 min read
·
Editorial Staff
Drug Development

Research Roundup: Pancreatic Cancer, Dementia Genes, Molecular Surgery and More

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

April 4, 2019
·
8 min read
·
Mark Terry
Job Trends

BioSpace Movers and Shakers: April 5

Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.

April 4, 2019
·
6 min read
·
Alex Keown
Drug Development

NIH Begins Trial of Potential Universal Flu Vaccine

According to the NIH, the experimental vaccine is designed to “teach the body to make protective immune responses against diverse influenza subtypes by focusing the immune system on a portion of the virus that varies relatively little from strain to strain.”

April 4, 2019
·
3 min read
·
Alex Keown
Policy

Sorrento Takes Aim at Billionaire Patrick Soon-Shiong, Files Lawsuit Over 2015 Cynviloq Deal

The lawsuit alleges that Soon-Shiong acquired the promising cancer treatment in order to prevent it from coming to market and challenging revenues from Celgene’s Abraxane, a drug Soon-Shiong developed.

April 4, 2019
·
3 min read
·
Alex Keown
Policy

Gottlieb Pushes Full Steam Ahead at the FDA

With the clock winding down on his tenure at the U.S. Food and Drug Administration, Commissioner Scott Gottlieb continues to take aim at a number of concerns he has raised over the past two years, including the dangers of vaping and unsanctioned use of stem cells.

April 4, 2019
·
3 min read
·
Alex Keown
Policy

$50 Million Judgment Against Omics Underlines Problem With Predatory Scientific Publishers

The U.S. Federal Trade Commission (FTC) won a suit against India-based scientific publisher, Omics International, alleging that the publisher operated hundreds of fake scientific journals with deceptive business practices.

April 4, 2019
·
4 min read
·
Mark Terry
Policy

Jazz Pharma, Lundbeck and Alexion Pay $122 Million to Settle Kickback Allegations

The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.

April 4, 2019
·
3 min read
·
Alex Keown